Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder
Authors:
Top Cited Papers
- 23 December 2023
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 240, 115937
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Evaluating vibegron for the treatment of overactive bladderExpert Opinion on Pharmacotherapy, 2020
- Validation of LC–MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric populationJournal of Pharmaceutical and Biomedical Analysis, 2019
- Determination of Mirabegron in rat plasma by UPLC–MS/MS after oral and intravenous administrationRevista da Associação Médica Brasileira, 2019
- Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder ( SYNERGY study)BJU International, 2017
- Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive BladderThe Journal of Pharmacology and Experimental Therapeutics, 2017
- Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY)World Journal of Urology, 2016
- Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic ReviewEuropean Urology, 2014
- Mirabegron: A Review of Its Use in Patients with Overactive Bladder SyndromeDrugs, 2013
- Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and WomenClinical Therapeutics, 2012
- Development and validation of LC–MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic studyJournal of Chromatography B, 2012